Isabell Matuschek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Isabell Matuschek has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Almut Schulze
Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
1 shared publicationAnn‐Cristin Berkemeier
Institute of Experimental Hematology and Transfusion Medicine Medical Faculty, University Hospital Bonn, University of Bonn Bonn Germany
1 shared publication- Behnaz Pezeshkpoor
Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany
1 shared publication Daniel Bexell
Translational Cancer Research, Lund University, 22381 Lund, Sweden
1 shared publication- Dolors Serra
Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
1 shared publication Ganna Oliynyk
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden
1 shared publication
Latest Publications
- Open Access
- 5 May 2025
- Published by Wiley in Haemophilia
- Vol. 31 (4) , 625-633
Profiling of Anti‐FVIII Antibodies in Acquired Haemophilia A: ‘Insights into Domain Specificity, Isotype Variability, and Clinical Correlations’
Introduction: Acquired haemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies against coagulation factor VIII (FVIII), resulting in significant bleeding risks. Aim: To characterize the anti‐FVIII antibody profile in AHA patients by assessing isotypes, subclasses, and correlations with key clinical parameters. Methods: Eighty AHA patients were retrospectively analysed by assessing FVIII inhibitor levels, antibody isotypes (IgG, IgA, IgM), IgG subclasses, and domain specificity using a bead‐based assay. Clinical data were correlated with antibody profiles. IgG domain profiles were compared with a congenital haemophilia A (CHA) cohort. Results: The cohort had a median age of 74 years, with 60% males. Idiopathic cases accounted for 67%, and 17% had bleeding linked to medical interventions. Major bleeding sites were musculoskeletal/retroperitoneal (45%) and skin (36%). Within six months, 18% of patients died, mostly from sepsis. Anti‐FVIII IgG antibodies were present in all patients, with IgG 4 (96%) and IgG 3 (60%) being the most common subclasses. IgM and IgA anti‐FVIII antibodies were detected in 17.5% and 18.8% of patients, respectively, with IgM positivity associated with higher mortality (33%). IgG 4 subclass correlated significantly with inhibitor titres ( r s = 0.54; p < 0.001). Compared to CHA, AHA showed a higher prevalence of C1C2 domain‐targeting antibodies (49% vs. 77%), associated with NBA levels ( r s = 0.51; p < 0.001). Conclusion: Anti‐FVIII antibody profiling reveals distinct patterns in AHA, with IgG 4 linked to higher inhibitor levels. The C1C2 domain specificity of the anti‐FVIII antibodies suggests a potential role of this FVIII domain in the immunopathology of AHA patients, warranting further investigation to improve prognostic tools.
- 5 May 2025
- Published by Wiley in Haemophilia
- Vol. 31 (4) , 625-633
Open AccessProfiling of Anti‐FVIII Antibodies in Acquired Haemophilia A: ‘Insights into Domain Specificity, Isotype Variability, and Clinical Correlations’
Introduction: Acquired haemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies against coagulation factor VIII (FVIII), resulting in significant bleeding risks. Aim: To characterize the anti‐FVIII antibody profile in AHA patients by assessing isotypes, subclasses, and correlations with key clinical parameters. Methods: Eighty AHA patients were retrospectively analysed by assessing FVIII inhibitor levels, antibody isotypes (IgG, IgA, IgM), IgG subclasses, and domain specificity using a bead‐based assay. Clinical data were correlated with antibody profiles. IgG domain profiles were compared with a congenital haemophilia A (CHA) cohort. Results: The cohort had a median age of 74 years, with 60% males. Idiopathic cases accounted for 67%, and 17% had bleeding linked to medical interventions. Major bleeding sites were musculoskeletal/retroperitoneal (45%) and skin (36%). Within six months, 18% of patients died, mostly from sepsis. Anti‐FVIII IgG antibodies were present in all patients, with IgG 4 (96%) and IgG 3 (60%) being the most common subclasses. IgM and IgA anti‐FVIII antibodies were detected in 17.5% and 18.8% of patients, respectively, with IgM positivity associated with higher mortality (33%). IgG 4 subclass correlated significantly with inhibitor titres ( r s = 0.54; p < 0.001). Compared to CHA, AHA showed a higher prevalence of C1C2 domain‐targeting antibodies (49% vs. 77%), associated with NBA levels ( r s = 0.51; p < 0.001). Conclusion: Anti‐FVIII antibody profiling reveals distinct patterns in AHA, with IgG 4 linked to higher inhibitor levels. The C1C2 domain specificity of the anti‐FVIII antibodies suggests a potential role of this FVIII domain in the immunopathology of AHA patients, warranting further investigation to improve prognostic tools.